Therapy Areas: Oncology
Oasmia Pharmaceutical appoints Francois Martelet as new CEO
17 February 2020 -

Oasmia Pharmaceutical AB (STO:OASM) (FRA:OMAX.GR) announced on Friday the appointment of Francois Martelet as the new CEO of the company.

Dr Martelet, who has extensive international experience of leading pharmaceutical companies, replaces Sven Rohmann, who has been acting CEO during a crucial transition period. Rohmann will remain in his position as board member and will continue to play an active role in the company's commercialisation strategy going forward.

Martelet has held three CEO positions in the last 12 years. He has spent most of his career in the oncology field, as CEO of Avax and Topotarget, as well as in executive roles at senior level at Roche, Eli Lilly, Novartis and MSD. He has been based in six countries in Europe (including Sweden) and in the US.

Oasmia Pharmaceutical develops, manufactures and markets new generations of drugs in the field of human and veterinary oncology.

Login
Username:

Password: